Novadip Initiates Pivotal Phase 3 Trial of NVD003 for Rare Pediatric Bone Condition
Key Insights
Novadip Biosciences has recruited the first pediatric patients for its pivotal phase 3 trial of NVD003, a tissue regenerative treatment for congenital pseudoarthrosis of the tibia (search) (CPT).
The trial aims to enroll 12 children across eight sites in the EU and US by Q1 2026, with previous studies showing seven of eight CPT patients achieved durable bone union.
CPT affects less than 3.5 in 150,000 live births and often leads to multiple failed surgeries and potential limb amputation without effective treatment.
Novadip Biosciences has achieved a significant milestone in regenerative medicine by recruiting the first pediatric patients for its pivotal phase 3 trial of NVD003, a tissue regeneration product designed to treat congenital pseudoarthrosis of the tibia (search) (CPT). Phoenix Children's Hospital in Arizona and Cliniques universitaires Saint-Luc in Brussels have each enrolled one patient—a toddler aged 3 and a teenager, respectively.
The Belgian late-stage clinical biotechnology company specializing in regenerative medicine announced the recruitment milestone on December 15, 2025, marking a critical advancement in addressing a rare pediatric condition that affects fewer than 3.5 in 150,000 live births.
Trial Design and Enrollment Strategy
The phase 3 trial will enroll at least 12 children with CPT fractures across eight sites in the European Union and United States by the end of Q1 2026. The study will measure clinical and radiological healing at 12 months post-graft surgery with NVD003, with consenting participants monitored for an additional four years to assess durability and safety.
Professor Pierre-Louis Docquier, pediatric orthopedic surgeon at Cliniques universitaires Saint-Luc, serves as the coordinating investigator. Dr. Mohan Belthur, pediatric orthopedic surgeon and clinical assistant professor at the University of Arizona College of Medicine in Phoenix, leads the trial at Phoenix Children's Hospital.
Additional recruiting sites include Loma Linda University Children's Health, LifeBridge Health, Mayo Clinic, hospital Necker-Enfants Malades in Paris, CHU Amiens-Picardie, and hospital Sant Joan de Déu in Barcelona.
Promising Early Results
Previous trials with NVD003 have demonstrated encouraging outcomes. Of eight children with CPT treated to date, seven achieved durable union after two to seven years of follow-up. Most patients had experienced multiple failed procedures prior to NVD003 treatment. The current trial will enroll pediatric patients regardless of whether they are undergoing their first or fifth surgical procedure.
"I'm so proud of our team and all our colleagues involved in getting us to this point," said Judy Ashworth, MD, chief medical officer of Novadip Biosciences. "Clinical development is challenging enough for more common diseases. It takes high motivation, commitment and resilience to implement a trial in a rare pediatric condition."
Understanding Congenital Pseudoarthrosis of the Tibia
CPT presents significant challenges for affected children and their families. Children with CPT are typically born with a bowing of the tibia that progresses to spontaneous fracture. Once a fracture occurs, subsequent fractures become likely, often happening between six and 18 months following minimal trauma or weight-bearing as children learn to walk.
The condition commonly requires multiple surgical procedures before fractured bones heal. Children with CPT face impaired mobility and years of corrective surgeries to repair and stabilize bones, with limb amputation representing a potential outcome when other treatments fail.
Regulatory Recognition and Development Timeline
Novadip has received substantial regulatory support for NVD003 development. The FDA granted Orphan Drug Designation and Rare Pediatric Designation in 2020, followed by Fast Track Designation in 2023 and Regenerative Medicine Advanced Therapy (RMAT) Designation in 2025.
"It has been a long road from discovery to finally starting this strategic phase 3 trial," said Denis Dufrane, MD, PhD, CEO and founder of Novadip Biosciences. "As the inventor of NVD003, I'm so excited that our pivotal trial has now launched, moving us closer to putting this technology on the market to help restore full mobility in children with CPT and to prevent amputations."
Expanding to Adult Applications
Novadip is working with the FDA and EMA to explore NVD003 use in other populations with critical size bone defects for limb-sparing applications. The company plans to initiate a phase 3 clinical trial in adults in Q3 2026, focusing on limb sparing associated with bone non-union (search) (BNU).
To date, nine adults with recalcitrant BNU following traumatic fractures have been treated with NVD003. The treatment has demonstrated safety and achieved bone healing in 88% of patients.
Technology Platform and Mechanism
NVD003 represents a three-dimensional osteogenic graft derived from autologous adipose-derived mesenchymal stem cells (search) combined with hydroxyapatite/beta-tricalcium phosphate particles. The treatment was specifically developed to improve bone healing in severe pathophysiological conditions including hypoxia, lack of mineralized callus formation, bone resorption, and low osteogenicity.
Commercial Outlook
Novadip is preparing a Series C funding round to accelerate late-stage development and drive commercialization of its innovative therapies. The company targets market availability of NVD003 for pediatric patients by the end of 2027 and for adult patients in 2029, with projected potential peak sales of $1.6 billion.
The company's pipeline includes NVDX3, an allogeneic bone grafting material currently in phase 1b/2a trials for trauma surgery and lumbar intervertebral spine fusion. The FDA has approved initiation of a phase 2b/3 Investigational New Drug trial with NVDX3 in level two cervical spine fusion.
Founded in 2013 in Belgium, Novadip has raised €116 million in equity and non-dilutive funding since inception, including financing from the European Investment Bank.